Search research articles
Contact Us
Filters
Showing results (91-100 of 181) with videos related to
Page
of 19
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 24, 2013
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer
Mary L Gemignani, Sujata Patil, Venkatraman E Seshan, et al.
Radiology
|
August 11, 2010
Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival
Evis Sala, Masako Kataoka, Neeta Pandit-Taskar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 17, 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
Neeta Pandit-Taskar, Joseph A O'Donoghue, Michael J Morris, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 8, 2020
Comparison of <sup>68</sup>Ga-DOTA-JR11 PET/CT with dosimetric <sup>177</sup>Lu-satoreotide tetraxetan (<sup>177</sup>Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
Simone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2021
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
George Sgouros, Yuni K Dewaraja, Freddy Escorcia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 11, 2022
Reply: Single-Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics
George Sgouros, Yuni K Dewaraja, Freddy Escorcia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 23, 2024
A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Dushen Chetty, et al.
Gynecologic Oncology
|
January 11, 2011
Sentinel lymph node biopsy in the management of early-stage cervical carcinoma
John P Diaz, Mary L Gemignani, Neeta Pandit-Taskar, et al.
NPJ Precision Oncology
|
February 13, 2026
Complete remission of relapsed ATXN2L::JAK2 fusion positive anaplastic large cell lymphoma following ruxolitinib monotherapy in a child
Tal Cohen, Ting Zhou, Ukuemi Edema, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 13, 2020
IntraOmmaya compartmental radioimmunotherapy using <sup>131</sup>I-omburtamab-pharmacokinetic modeling to optimize therapeutic index
Rahul S Yerrabelli, Ping He, Edward K Fung, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 181) with videos related to
Sort By:
Page
of 19
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 24, 2013
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer
Mary L Gemignani, Sujata Patil, Venkatraman E Seshan, et al.
Radiology
|
August 11, 2010
Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival
Evis Sala, Masako Kataoka, Neeta Pandit-Taskar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 17, 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
Neeta Pandit-Taskar, Joseph A O'Donoghue, Michael J Morris, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 8, 2020
Comparison of <sup>68</sup>Ga-DOTA-JR11 PET/CT with dosimetric <sup>177</sup>Lu-satoreotide tetraxetan (<sup>177</sup>Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
Simone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2021
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
George Sgouros, Yuni K Dewaraja, Freddy Escorcia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 11, 2022
Reply: Single-Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics
George Sgouros, Yuni K Dewaraja, Freddy Escorcia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 23, 2024
A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Dushen Chetty, et al.
Gynecologic Oncology
|
January 11, 2011
Sentinel lymph node biopsy in the management of early-stage cervical carcinoma
John P Diaz, Mary L Gemignani, Neeta Pandit-Taskar, et al.
NPJ Precision Oncology
|
February 13, 2026
Complete remission of relapsed ATXN2L::JAK2 fusion positive anaplastic large cell lymphoma following ruxolitinib monotherapy in a child
Tal Cohen, Ting Zhou, Ukuemi Edema, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 13, 2020
IntraOmmaya compartmental radioimmunotherapy using <sup>131</sup>I-omburtamab-pharmacokinetic modeling to optimize therapeutic index
Rahul S Yerrabelli, Ping He, Edward K Fung, et al.
Page
of 19